A downtrend has been apparent in Rigel Pharmaceuticals (RIGL) lately with too much selling pressure. The stock has declined 28.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ...

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS , /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion phase of the ongoing Phase 1b study of R289 in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). R289 is Rigel's potent a ...

文章核心观点 - 人工智能是巨大的投资机会，但其发展面临能源危机，为能源基础设施公司创造了机遇 [1][2][3] - 一家未被市场充分关注的公司，因其在能源基础设施领域的核心地位、无债务状况及持有其他AI公司股权，被视为极具吸引力的投资标的 [3][8][9] - 该公司业务横跨AI能源需求、美国液化天然气出口、制造业回流及核能领域，将受益于多重趋势 [5][6][7][14] AI行业能源需求 - AI是史上最耗电的技术，单个大型语言模型数据中心的耗电量堪比一座小型城市 [2] - AI的快速发展正将全球电网推向极限，OpenAI创始人Sam Altman警告AI的未来取决于能源突破，Elon Musk预测明年AI将面临电力短缺 [2] 目标公司业务定位 - 公司拥有关键的能源基础设施资产，将直接受益于AI数据中心激增的电力需求 [3][7] - 公司是美国液化天然气出口领域的关键参与者，将受益于“美国优先”能源政策带来的出口增长 [5][7] - 公司具备在石油、天然气、可再生燃料和工业基础设施领域执行大型复杂EPC项目的能力 [7] - 公司在核能领域拥有独特布局，核能被视为未来清洁可靠的电力来源 [7][14] 公司财务状况与估值 - 公司完全无负债，并持有相当于其总市值近三分之一的巨额现金储备 [8] - 公司持有另一家热门AI公司的巨额股权，为投资者提供了间接的AI增长敞口 [9] - 剔除现金和投资后，公司交易市盈率低于7倍，估值极具吸引力 [10] 宏观趋势与催化剂 - 特朗普政府的关税政策将推动制造业回流美国，公司将为回流企业提供重建、改造和再工程服务 [5] - AI基础设施超级周期、制造业回流浪潮、美国液化天然气出口激增以及核能发展共同构成公司的增长动力 [14]

Key Takeaways Rigel's Tavalisse posted $68.5M in H1 2025 sales, which increased 44% year over year.Rezlidhia sales rose 31% to $13.1M, with Gavreto adding incremental revenues in 1H 2025.R289 phase Ib study in MDS moves to dose expansion, with dose escalation data expected later in 2025.Rigel Pharmaceuticals (RIGL) is making continued advancement related to the development of its hematology and oncology pipeline and products. The company’s first product, Tavalisse (fostamatinib disodium hexahydrate), has be ...

Rigel Pharmaceuticals (RIGL) has been beaten down lately with too much selling pressure. While the stock has lost 27% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and chang ...

Rigel Pharmaceuticals (NASDAQ: RIGL ) is a commercial-stage biotechnology company that is developing oral small-molecule kinase inhibitors, which are used to help treat blood disorders and certain cancers. Despite having three commercialized products and marginsMy career in the world of investing began at an early age, fueled by the potential for profits, I first began investing at the age of 11 with the help of my father. I first began picking stocks by looking at what was going to logically make money, an ...

Key Takeaways RIGL's Tavalisse drove $68.5M sales in H1 2025, up 44% year over year, driving top-line growth.RIGL raised its 2025 revenue outlook to $270-$280M on strong performance across its marketed products.FOLD's Galafold posted $233.1M H1 2025 sales, up 11% year over year, with patent protection to 2038.Both Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are developing and commercializing treatments for rare medical conditions where existing therapies are limited, with the goal of establi ...

Key Takeaways Rigel stock has jumped 76.7% in three months, fueled by strong momentum for Tavalisse.Tavalisse made up over 65% of net product sales in Q2 2025, the firm's best quarter yet.Rigel raised 2025 revenue guidance to $270-$280M, led by Tavalisse, Rezlidhia and Gavreto.Shares of Rigel Pharmaceuticals (RIGL) have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s lead drug, Tavalisse (fostamatini ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported its fiscal Q2 2025 results on August 5, with total revenue for the quarter reaching approximately $101.7 million. This included net product sales of $58.9 million and contract revenues from collaborations of $42.7 million. The company also generated $59.6 million in net income. Following the results, Jefferies analyst Eun Yang maintained a Hold ratin ...

Key Takeaways Tavalisse recorded $68.5M in H1 sales, up 44% year over year on strong new patient demand.Rigel raised the 2025 revenue forecast to $270-$280M, up from the prior guidance of $200-$210M.Rigel's other marketed products, Rezlidhia and Gavreto, also saw sales increases in H1 2025.Rigel Pharmaceuticals’ (RIGL) first product, Tavalisse (fostamatinib disodium hexahydrate), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.Tavalisse, an ora ...